Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial.
暂无分享,去创建一个
Giampiero Girolomoni | Mauro Zamboni | P. Gisondi | G. Girolomoni | M. Zamboni | M. del Giglio | Paolo Gisondi | Vincenzo Di Francesco | Micol Del Giglio | V. Di Francesco
[1] P. Venge,et al. A fasting and vegetarian diet treatment trial on chronic inflammatory disorders. , 1983, Acta dermato-venereologica.
[2] J. Bastard,et al. Adipokines: the missing link between insulin resistance and obesity. , 2008, Diabetes & metabolism.
[3] A. Rissanen,et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. , 2008, European journal of endocrinology.
[4] R. Mensink,et al. Weight loss, but not fish oil consumption, improves fasting and postprandial serum lipids, markers of endothelial function, and inflammatory signatures in moderately obese men. , 2007, The Journal of nutrition.
[5] Tosca L. Zern,et al. Weight Loss Favorably Modifies Anthropometrics and Reverses the Metabolic Syndrome in Premenopausal Women , 2005, Journal of the American College of Nutrition.
[6] V. Ho,et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. , 1999, The British journal of dermatology.
[7] L. Färber,et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. , 1995, Journal of the American Academy of Dermatology.
[8] B. Gersh. Risk of Myocardial Infarction in Patients With Psoriasis , 2007 .
[9] A. Finlay,et al. Ciclosporin in psoriasis clinical practice: an international consensus statement , 2004, The British journal of dermatology.
[10] T. Hayakawa,et al. Effect of obesity on cyclosporine trough concentrations in psoriasis patients. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[11] L. Dubertret,et al. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun®) for long‐term treatment of chronic severe plaque psoriasis , 1994, The British journal of dermatology.
[12] Sang Mi Ahn,et al. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. , 2008, The Journal of nutritional biochemistry.
[13] M. Haugen,et al. Vegetarian diet for patients with rheumatoid arthritis — Status: Two years after introduction of the diet , 1994, Clinical Rheumatology.
[14] M. Maniscalco,et al. Weight loss and asthma control in severely obese asthmatic females. , 2008, Respiratory medicine.
[15] J. Koo. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. , 1998, The British journal of dermatology.
[16] Parvez Hossain,et al. Obesity and diabetes in the developing world--a growing challenge. , 2007, The New England journal of medicine.
[17] Akira Nagano,et al. Calorie restricted diet and urinary pentosidine in patients with rheumatoid arthritis. , 2004, Journal of physiological anthropology and applied human science.
[18] O. Førre,et al. Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis , 1991, The Lancet.
[19] M. Lebwohl,et al. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. , 2008, Journal of the American Academy of Dermatology.
[20] B. Thiers. Impact of Obesity and Smoking on Psoriasis Presentation and Management , 2006 .
[21] T. Annesley,et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. , 1991, The New England journal of medicine.
[22] F. Granath,et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients , 2003, European Journal of Epidemiology.
[23] Griffiths,et al. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1‐year multicentre, randomized study , 1999 .
[24] G. Hotamisligil,et al. Inflammation and metabolic disorders , 2006, Nature.
[25] D. Beri,et al. Effect of dietary restrictions on disease activity in rheumatoid arthritis. , 1988, Annals of the rheumatic diseases.
[26] L. Färber,et al. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. , 1997, Acta dermato-venereologica.
[27] M. Weichenthal,et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis , 2006, Archives of Dermatological Research.
[28] N. Schork,et al. Alcohol intake and treatment responsiveness of psoriasis: a prospective study. , 1993, Journal of the American Academy of Dermatology.
[29] M. Neves,et al. Remission of Psoriasis after Open Gastric Bypass , 2006, Obesity surgery.
[30] U. Mrowietz,et al. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. , 1992, Journal of the American Academy of Dermatology.
[31] L. Niskanen,et al. Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome. , 2008, Metabolism: clinical and experimental.
[32] H. Yoon,et al. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis , 2007, The Journal of dermatological treatment.
[33] B. Thiers. Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women: Nurses' Health Study II , 2008 .
[34] A. Goldfine,et al. Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.
[35] K. Schechtman,et al. Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. , 2006, The American journal of clinical nutrition.
[36] F. G. Benedict,et al. A biometric study of basal metabolism in man , 2010 .
[37] Samuel Szomstein,et al. Psoriasis Remission after Laparoscopic Roux-En-Y Gastric Bypass for Morbid Obesity , 2004, Obesity surgery.
[38] B. Nicklas,et al. Inflammatory Biomarkers and Physical Function in Older, Obese Adults with Knee Pain and Self‐Reported Osteoarthritis After Intensive Weight‐Loss Therapy , 2008, Journal of the American Geriatrics Society.
[39] J. Koo,et al. A randomized, double‐blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis , 1998, The British journal of dermatology.
[40] R. Kaufmann,et al. Body-Weight-Independent Dosing of Cyclosporine Micro-Emulsion and Three Times Weekly Maintenance Regimen in Severe Psoriasis , 2002, Dermatology.
[41] Hyon K. Choi,et al. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. , 2007, Archives of internal medicine.
[42] B. Strober,et al. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review , 2007, The British journal of dermatology.
[43] S. Piaserico,et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study , 2007, The British journal of dermatology.
[44] L. Naldi,et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. , 2005, The Journal of investigative dermatology.
[45] T. Reunala,et al. Alcohol intake: a risk factor for psoriasis in young and middle aged men? , 1990, BMJ.
[46] Daniel B. Shin,et al. Prevalence of cardiovascular risk factors in patients with psoriasis. , 2006, Journal of the American Academy of Dermatology.
[47] Corby K. Martin,et al. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. , 2006, JAMA.
[48] P. Bossuyt,et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. , 2003, The New England journal of medicine.